Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris.
Biomarker
Endocan
Endothelial cell-specific molecule 1
Inflammation
Journal
Acta Cardiologica Sinica
ISSN: 1011-6842
Titre abrégé: Acta Cardiol Sin
Pays: China (Republic : 1949- )
ID NLM: 101687085
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
entrez:
24
3
2020
pubmed:
24
3
2020
medline:
24
3
2020
Statut:
ppublish
Résumé
Endothelial cell-specific molecule 1 (ESM-1 or endocan) is an immunoinflammatory marker strongly associated with inflammation, vascular endothelial dysfunction and atherosclerosis. We explored the relationship between serum endocan concentrations and coronary in-stent restenosis (ISR). Fifty consecutive patients with ISR and 50 control subjects were included in this study. Clinical data and angiographic characteristics were collected. Serum endocan concentrations were measured using an enzyme-linked immunosorbent assay. All included patients were divided into four quartiles based on their concentrations of endocan: quartile 1 (0.62-1.31 ng/mL), quartile 2 (1.33-1.74 ng/mL), quartile 3 (1.75-2.77 ng/mL) and quartile 4 (2.78-4.24 ng/mL). The rates of ISR were 16%, 24%, 68%, and 92%, respectively. The patients in quartile 4 had significantly higher rates of ISR than the other groups (p < 0.001). Logistic regression analysis indicated that endocan concentration [odds ratio = 8.65, 95% confidence interval 3.56-20.94; p < 0.001] was an independent predictor of ISR. Receiver operating characteristic curve analysis was used to explore the relationship between endocan and ISR. Using a cutoff value of 1.625 ng/mL, endocan predicted ISR with a sensitivity of 86% and a specificity of 78%. Our findings suggest that plasma endocan levels may be a novel biomarker of endothelial dysfunction in patients with ISR.
Sections du résumé
BACKGROUND
BACKGROUND
Endothelial cell-specific molecule 1 (ESM-1 or endocan) is an immunoinflammatory marker strongly associated with inflammation, vascular endothelial dysfunction and atherosclerosis. We explored the relationship between serum endocan concentrations and coronary in-stent restenosis (ISR).
METHODS
METHODS
Fifty consecutive patients with ISR and 50 control subjects were included in this study. Clinical data and angiographic characteristics were collected. Serum endocan concentrations were measured using an enzyme-linked immunosorbent assay.
RESULTS
RESULTS
All included patients were divided into four quartiles based on their concentrations of endocan: quartile 1 (0.62-1.31 ng/mL), quartile 2 (1.33-1.74 ng/mL), quartile 3 (1.75-2.77 ng/mL) and quartile 4 (2.78-4.24 ng/mL). The rates of ISR were 16%, 24%, 68%, and 92%, respectively. The patients in quartile 4 had significantly higher rates of ISR than the other groups (p < 0.001). Logistic regression analysis indicated that endocan concentration [odds ratio = 8.65, 95% confidence interval 3.56-20.94; p < 0.001] was an independent predictor of ISR. Receiver operating characteristic curve analysis was used to explore the relationship between endocan and ISR. Using a cutoff value of 1.625 ng/mL, endocan predicted ISR with a sensitivity of 86% and a specificity of 78%.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that plasma endocan levels may be a novel biomarker of endothelial dysfunction in patients with ISR.
Identifiants
pubmed: 32201461
doi: 10.6515/ACS.202003_36(2).20190731A
pmc: PMC7062819
doi:
Types de publication
Journal Article
Langues
eng
Pagination
111-117Références
J Thorac Dis. 2016 Oct;8(10):E1150-E1162
pubmed: 27867580
J Investig Med. 2015 Oct;63(7):867-70
pubmed: 26200037
Circulation. 1999 Sep 7;100(10):1109-15
pubmed: 10477537
Angiology. 2016 Oct;67(9):846-53
pubmed: 26744512
Kidney Int. 2014 Dec;86(6):1213-20
pubmed: 24988065
Angiology. 2017 Apr;68(4):354-359
pubmed: 27225701
J Am Coll Cardiol. 2003 Oct 1;42(7):1149-60
pubmed: 14522472
Acta Cardiol Sin. 2019 Jan;35(1):65-74
pubmed: 30713401
J Cell Physiol. 2014 May;229(5):620-30
pubmed: 24446198
Angiology. 2016 Sep;67(8):749-55
pubmed: 26614790
Biochim Biophys Acta. 2006 Jan;1765(1):25-37
pubmed: 16168566
Kidney Int. 2014 Dec;86(6):1079-81
pubmed: 25427083
Atherosclerosis. 2015 Nov;243(1):339-43
pubmed: 26448266
Angiology. 2015 Sep;66(8):727-31
pubmed: 25168956
J R Soc Interface. 2011 May 6;8(58):641-9
pubmed: 21106574
J Am Coll Cardiol. 2010 Nov 23;56(22):1783-93
pubmed: 21087705
Heart. 2007 Sep;93(9):1087-92
pubmed: 17309906
Nepal Med Coll J. 2005 Dec;7(2):101-6
pubmed: 16519074
Eur Radiol. 2013 Jan;23(1):101-7
pubmed: 22772148
Acta Pharm. 2012 Dec;62(4):473-96
pubmed: 23333885
Angiology. 2017 Jan;68(1):46-51
pubmed: 27178721
Acta Cardiol Sin. 2018 May;34(3):224-232
pubmed: 29844643
Angiology. 2014 Oct;65(9):773-7
pubmed: 24402320